Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial

Xiao,Jie; Zhou,Jian; Fu,Min; Liang,Li; Deng,Qiaoling; Liu,Xiaoyun; Liu,Fumin

doi:10.3892/ol.2017.5901

Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial

Authors:
- Jie Xiao
- Jian Zhou
- Min Fu
- Li Liang
- Qiaoling Deng
- Xiaoyun Liu
- Fumin Liu
View Affiliations

Affiliations: Department of Gynecology, Xuzhou Maternity and Child Health Care Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China , Cervical Disease Center, Xuzhou Maternity and Child Health Care Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China, Center Laboratory, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China, Department of Obstetrics and Gynecology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China
Published online on: March 24, 2017 https://doi.org/10.3892/ol.2017.5901
Pages: 3676-3680
Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the efficacy and safety of recombinant human adenovirus-p53 (rhAd‑p53) combined with neoadjuvant chemotherapy in treatment of locally advanced cervical cancer (LACC). A total of 40 patients with LACC (stage IB2 to IIIA) were randomized into 2 groups (n=20 each): PVB group (cisplatin + vincristine + bleomycin, intravenously) and combined group (rhAd‑p53 gene therapy + neoadjuvant chemotherapy). Both groups underwent a course of chemotherapy; the only exception was the injection of the rhAd‑p53 solution 1x1012 VP intratumorally at an interval of three days thrice in the combined group thereafter. The tumor sizes and adverse events in both groups were observed. The expression of vascular endothelial growth factor (VEGF), protein p53 and micro‑vessel density (MVD) in tumor tissue was respectively determined by immunohistochemistry. The evaluation was performed three weeks after the completion of chemotherapy. The efficacy was 75% in the PVB group versus 95% efficacy in the combined group; the tumor size was reduced by 11.42±2.78 cm2 in PVB group versus the significant shrinkage of 15.25±4.00 cm2 in the combined group (P<0.05). The expression of VEGF, p53 and MVD was downregulated in both the PVB and combined groups, with significantly statistical differences versus the control. No additional adverse events were evidenced in the combined group. Therefore, intratumoral injection of rhAd‑p53 combined with neoadjuvant chemotherapy has advantage over conventional chemotherapy for its high efficacy, safety and synergism in the therapy for LACC.

View Figures

View References

1	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
2	Rydzewska L, Tierney J, Vale CL and Symonds PR: Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 12:CD0074062012.PubMed/NCBI
3	Gadducci A, Sartori E, Maggino T, Zola P, Cosio S, Zizioli V, Lapresa M, Piovano E and Landoni F: Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: An Italian multicenter retrospective study (CTF Study). Gynecol Oncol. 131:640–644. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, Baselga J, Murphy BA, et al: Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res. 15:7719–7725. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lehmann BD and Pietenpol JA: Targeting mutant p53 in human tumors. J Clin Oncol. 30:3648–3650. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zheng XL, Wang TT, Fu M, Zhou J and Liu FM: Inhibitory effect of recombinant human adenovirus-P53 combined with paclitaxel on human cervical cancer HeLa cells and its mechanism. Chin J Cancer Biother. 20:192–196. 2013.(In Chinese).
7	Lane DP, Cheok CF and Lain S: p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2:a0012222010. View Article : Google Scholar : PubMed/NCBI
8	Burdak-Rothkamm S, Rothkamm K, McClelland K, Al Rashid ST and Prise KM: BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells. Cancer Lett. 356(Pt B 2): 454–461. 2015. View Article : Google Scholar : PubMed/NCBI
9	Jiang G, Xin Y, Zheng JN and Liu YQ: Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: A novel antitumor approach. Int J Cancer. 129:263–274. 2011. View Article : Google Scholar : PubMed/NCBI
10	Prados J, Alvarez PJ, Melguizo C, Rodriguez-Serrano F, Carrillo E, Boulaiz H, Vélez C, Marchal JA, Caba O, Ortiz R, et al: How is gene transfection able to improve current chemotherapy? The role of combined therapy in cancer treatment. Curr Med Chem. 19:1870–1888. 2012. View Article : Google Scholar : PubMed/NCBI
11	Wirth T, Parker N and Ylä-Herttuala S: History of gene therapy. Gene. 525:162–169. 2013. View Article : Google Scholar : PubMed/NCBI
12	Tassone P, Old M, Teknos TN and Pan Q: p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol. 49:733–737. 2013. View Article : Google Scholar : PubMed/NCBI
13	Li D, Zhang Y, Xie Y, Xiang J, Zhu Y and Yang J: Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer. Cancer Gene Ther. 20:251–259. 2013. View Article : Google Scholar : PubMed/NCBI
14	Chen GX, Zheng LH, Liu SY and He XH: rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. World J Gastroenterol. 17:4289–4297. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cao Y, Guangqi E, Wang E, Pal K, Dutta SK, Bar-Sagi D and Mukhopadhyay D: VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72:3912–3918. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, Panici P Benedetti and Tomao S: Angiogenesis and antiangiogenic agents in cervical cancer. Onco Targets Ther. 7:2237–2248. 2014. View Article : Google Scholar : PubMed/NCBI
17	Perrot-Applanat M and Di Benedetto M: Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion. Cell Adhes Migr. 6:547–553. 2012. View Article : Google Scholar
18	Holmgren L, Jackson G and Arbiser J: p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene. 17:819–824. 1998. View Article : Google Scholar : PubMed/NCBI
19	Li X, Xiao S, Li Y and Zhang S: Clinical antiangiogenic effect of recombinant adenovirus-p53 combined with hyperthermia for advanced cancer. Chin J Cancer Res. 25:749–755. 2013.PubMed/NCBI
20	Crinelli R, Bianchi M, Menotta M, Carloni E, Giacomini E, Pennati M and Magnani M: Ubiquitin over-expression promotes E6AP autodegradation and reactivation of the p53/MDM2 pathway in HeLa cells. Mol Cell Biochem. 318:129–145. 2008. View Article : Google Scholar : PubMed/NCBI
21	Yang X and Lu L: Expression of HPV-16 E6 protein and p53 inactivation increases the uterine cervical cancer invasion. Drug Res (Stuttg). 65:70–73. 2015.PubMed/NCBI
22	Yu YF, Zhang Y, Shen N, Zhang RY and Lu XQ: Effect of VEGF, P53 and telomerase on angiogenesis of gastric carcinoma tissue. Asian Pac J Trop Med. 7:293–296. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ding S, Li C, Lin S, Yang Y, Liu D, Han Y, Zhang Y, Li L, Zhou L and Kumar S: Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol. 37:861–866. 2006. View Article : Google Scholar : PubMed/NCBI